FibroGen licenses anemia drug to AstraZeneca in potential $815M deal AstraZeneca secured the rights to develop and market FibroGen's late-stage anemia drug candidate FG-4592 in the U.S., China and certain other markets. The small molecule hypoxia-inducible factor inhibitor is the first of a new class of treatment designed to increase red blood cell production by triggering the body's response to high altitude conditions. FibroGen is eligible to receive $350 million upfront and as much as $465 million in milestone fees plus sales royalties, with more payments possible if approved indications go beyond anemia related to kidney disease. Reuters (7/31), PharmaTimes (U.K.) (7/31)  | Report Track & Traceability
Commerce in Motion and JDA, surveyed 130 quality control, supply chain and operations professionals. The goal was to understand their ability to effectively track, trace, and recall products. Per the study financial cost is the greatest risk associated with the inability to trace items. Download the free report now to see where the Life Sciences industry stands on traceability. |
 | Nearly 450 drugs for neurological disorders are in the pipeline Pharmaceutical Research and Manufacturers of America reported Wednesday that 444 drugs intended to treat neurological disorders are in clinical development or being reviewed by the FDA. "Despite the incredible complexity of neurological disorders, biopharmaceutical scientists have delivered significant advances for patients in recent years, including new medicines for multiple sclerosis and Huntington's diseases," said John J. Castellani, PhRMA's president and CEO. Drug Store News (7/31) Don't ignore irresponsible denials of advances in drugs, patient care The "foolish" statements made by Donald W. Light of the University of Medicine & Dentistry of New Jersey against the FDA and the pharmaceutical industry can't be ignored, John LaMattina writes. Light, who said that around 90% of all new approved treatments in the past 30 years are less or no more effective than existing treatments, ignores great advances in the care and treatment of patients with HIV, cancer and cardiovascular disease, LaMattina writes. Forbes (7/30)
Stem cells produce blood vessels using novel vasculogenic method Researchers at Massachusetts General Hospital and Harvard University were able to produce endothelial cells and multipotent stromal cells from human induced pluripotent stem cells and use them to generate blood vessels in vivo. "To our knowledge, this is the first report demonstrating the use of triple selection markers CD34, NP1 and KDR for the isolation of vasculogenic precursor cells from human induced pluripotent stem cells that are, most importantly, highly potent in an in vivo setting," according to one of the researchers. MedicalXpress.com (7/30) | | Industrial & Environmental | | Register today for the BIO Investor Forum, Oct. 8-9, in San Francisco The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One partnering meetings. BIO is renowned for its successful business development, partnering and investor meetings in North America, Europe and Asia. Partnering at this conference will be powered by BIO One-on-One Partnering, an interactive environment to intelligently search, contact and schedule private meetings with potential partners and investors. Register today. |  | We choose our joys and sorrows long before we experience them." -- Khalil Gibran, Lebanese-American artist, poet and writer | | | The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com. | Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
| Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | |
No comments:
Post a Comment